11. Segment Information Segment Reporting (Tables)

3 Months Ended

9 Months Ended

Sep. 30, 2020

Sep. 30, 2020

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Information regarding operating segments for the three months ended September 30, 2020 and 2019 is as follows (in millions):

		Life Science		Clinical Diagnostics		Other Operations
Segment net sales	2020	$	324.0	$	322.2	$	1.1
	2019	$	215.7	$	341.8	$	3.1
Segment net profit (loss)	2020	$	70.3	$	38.0	$	(0.8)
	2019	$	11.6	$	43.8	$	(0.4)

Information regarding operating segments for the nine months ended September 30, 2020 and 2019 is as follows (in millions):

		Life Science		Clinical Diagnostics		Other Operations
Segment net sales	2020	$	803.2	$	945.6	$	7.0
	2019	$	643.9	$	1,032.9	$	10.4
Segment net profit (loss)	2020	$	128.3	$	100.9	$	(0.2)
	2019	$	45.9	$	117.1	$	(1.1)

Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]

The following reconciles total segment profit to consolidated income before income taxes (in millions):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2020		2019		2020		2019
Total segment profit	$	107.5	$	55.0	$	229.0	$	161.9
Foreign currency exchange losses, net	(0.8)		(0.9)		(2.5)		(3.4)
Net corporate operating and other expense not allocated to segments	(3.6)		(3.1)		(10.4)		(8.8)
Change in fair market value of equity securities	1,580.4		(390.6)		3,591.5		1,385.0
Other income, net	1.0		4.4		21.5		27.0
Consolidated income (loss) before income taxes	$	1,684.5	$	(335.2)	$	3,829.1	$	1,561.7